Indian biotechnology company and vaccine maker Bharat Biotech International Limited (Bharat Biotech) has resumed export of its COVID-19 shot, Covaxin, and has executed long-pending orders in November 2021, Reuters news agency reported on Monday.
According to a statement on Twitter, the company also said exports to additional countries will commence from December 2021.
However, it was not immediately clear whether or not these exports were made under the global vaccine-sharing facility COVAX.
Covaxin, which is 78% effective against severe cases of COVID-19, was approved for emergency use listing by the World Health Organisation earlier this month.
On 26 November 2021, India restarted exports of COVID-19 shots to COVAX for the first time since April 2021.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine